Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -359.76% is 76% below its 4-year average of -204.45%, near the low end of its 4-year range (-1867.95%–10703.50%).
123.16% below its 12-month average of 1553.29%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 10703.50%.
EBITDA MARGIN
-359.76%
EBITDA MARGIN AVG TTM
1553.29%
EBITDA MARGIN AVG 3Y
-184.69%
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-123.16%
CURRENT VS 3Y AVG
-94.79%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Metagenomi, Inc. Common Stock
Market Cap
$39.94M
EBITDA Margin
-359.76%
TTM Avg
1553.29%
3Y Avg
-184.69%
5Y Avg
N/A
Market Cap
$38.88M
EBITDA Margin
6.14%
TTM Avg
3.48%
3Y Avg
3.86%
5Y Avg
5.21%
Market Cap
$37.75M
EBITDA Margin
-27375.58%
TTM Avg
-138216.12%
3Y Avg
-92142.37%
5Y Avg
-55460.65%
Market Cap
$37.67M
EBITDA Margin
-1929.22%
TTM Avg
-1308.49%
3Y Avg
-1783.80%
5Y Avg
-1343.37%
Market Cap
$42.36M
EBITDA Margin
-0.99%
TTM Avg
4.72%
3Y Avg
-25.09%
5Y Avg
-32.37%
Market Cap
$43.04M
EBITDA Margin
14.14%
TTM Avg
17.13%
3Y Avg
-2.79%
5Y Avg
-117.76%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Metagenomi, Inc. Common Stock (MGX) | $39.94M | -359.76% | 1553.29% | -184.69% | N/A |
| Nephros, Inc. (NEPH)vs › | $39.84M | 6.84% | 3.92% | -9.89% | -19.41% |
| Filana Therapeutics, Inc. (FLNA)vs › | $40.35M | N/A | N/A | N/A | N/A |
| Harvard Bioscience, Inc. (HBIO)vs › | $38.88M | 6.14% | 3.48% | 3.86% | 5.21% |
| Precipio, Inc. (PRPO)vs › | $41.92M | 2.29% | -7.32% | -44.00% | -66.61% |
| Incannex Healthcare Limited (IXHL)vs › | $37.75M | -27375.58% | -138216.12% | -92142.37% | -55460.65% |
| Edesa Biotech, Inc. (EDSA)vs › | $37.67M | -1929.22% | -1308.49% | -1783.80% | -1343.37% |
| BioStem Technologies, Inc. (BSEM)vs › | $42.36M | -0.99% | 4.72% | -25.09% | -32.37% |
| SANUWAVE Health Inc. (SNWV)vs › | $43.04M | 14.14% | 17.13% | -2.79% | -117.76% |
| QT Imaging Holdings, Inc. (QTI)vs › | $36.76M | -22.75% | -133.81% | -3828.74% | -3288.72% |
Gross Margin
74.3%
EBITDA Margin
-359.8%
Operating Margin
-380.9%
Net Margin
-689.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 10703.50% |
| 2026-03-31 | -1867.95% |
| 2025-12-31 | -589.80% |
| 2025-09-30 | -248.47% |
| 2025-06-30 | -230.85% |
| 2025-03-31 | -641.19% |
| 2024-12-31 | -199.31% |
| 2024-09-30 | -182.55% |
| 2024-06-30 | -77.74% |
| 2024-03-31 | -248.76% |
| 2023-12-31 | -153.20% |
| 2023-09-30 | -171.81% |
| 2023-06-30 | -149.53% |
| 2023-03-31 | -197.49% |
| 2022-12-31 | -268.94% |
| 2022-09-30 | -211.38% |
| 2022-06-30 | -261.13% |
| 2022-03-31 | -261.13% |
